Yasmin M Abaza

25PUBLICATIONS
170CO-AUTHORS
Haematological tumoursRegenerative medicine (incl. stem cells)Gene and molecular therapyMedical infection agents (incl. prions)Cancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (25)

|Aug 31, 2026
Choice of hypomethylating agent for newly diagnosed TP53-mutant acute myeloid Leukemia: a COMMAND registry study.

|Aug 27, 2026
Impact of Response to Hypomethylating Agent-Based Therapy on Survival Outcomes in the Context of Baseline Clinical-Molecular Risk and Transplant Status in Patients With Higher-Risk Myelodysplastic Syndromes/Neoplasms: An analysis From the International Consortium for MDS (icMDS).

|Jul 02, 2026
Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model.

|Jun 29, 2026
Outcomes of patients with higher-risk myelodysplastic syndromes/neoplasms treated with hypomethylating agents + venetoclax-an analysis from the International Consortium for MDS (icMDS) VALIDATE database.

|Apr 15, 2026
PTP4A2 promotes leukemogenesis through inhibiting the p53 tumor suppressor signaling pathway in leukemia-initiating cells.

|Dec 06, 2025
Outcomes of relapsed or refractory acute myeloid leukemia after menin inhibition failure.

Kuo-Kai Chin, Brian J Ball, Yasmin Abaza

Pageof 5

Frequent Collaborators

10 joint publications

Talha Badar

9 joint publications

Anand Patel

6 joint publications

Vamsi Kota

6 joint publications

Jan Philipp Bewersdorf